John Goertz
Optometrist · Omaha, NENPI 1699709006
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,941 of the $8,170 with a category attached, or 72.7%. 24 manufacturers reported payments, led by Glaukos Corporation at 41.0% of the total. Reporting peaked in 2022 at $3,629 and has fallen 69.9% since, to $1,093 in 2025. Among optometrist clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 178 payments — averaging $45.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$3K
- Alcon$880
- AbbVie$630
- Biotissue Holdings Inc.$558
- Amgen$357
- Mallinckrodt Hospital Products Inc.$333
- plus $2K from 18 others
What the payments were for
- Consulting fees$2,03025%
- Speaking & faculty fees$531%
- Food & beverage$5,94173%
- Education$1462%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 27 | $3,351 |
| Alcon | 30 | $880 |
| AbbVie(2 entities) | 29 | $630 |
| Biotissue Holdings Inc. | 7 | $558 |
| Amgen(2 entities) | 15 | $357 |
| Mallinckrodt Hospital Products Inc. | 10 | $333 |
| Bausch & Lomb Americas Inc. | 11 | $308 |
| Oyster Point Pharma, Inc. | 4 | $284 |
| Tarsus Pharmaceuticals, Inc. | 8 | $214 |
| Optos, Inc. | 1 | $185 |
| Sun Pharmaceutical Industries Inc. | 5 | $164 |
| Kala Pharmaceuticals, Inc. | 2 | $138 |
| Samsara Vision | 1 | $136 |
| Sight Sciences, Inc. | 2 | $129 |
| Rxsight Inc | 6 | $119 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $90 |
| Dompe US, Inc. | 4 | $73 |
| Rayner Intraocular Lenses Limited | 3 | $71 |
| Novartis | 3 | $55 |
| Omeros Corporation | 2 | $28 |
| Ivantis, Inc | 1 | $21 |
| Harrow Eye, LLC | 1 | $20 |
| Aerie Pharmaceuticals, Inc. | 1 | $18 |
| The Cameron-ehlen Group, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PANORAMIC OPHTHALMOSCOPE$371
- Prokera$277
- AmnioGraft$277
- iStent inject W$261
- KXL System$261
- Photrexa$261
- TYRVAYA$247
- iDoseTR$187
- OCT OPHTHALMOSCOPE$185
- NFC-700$185
- Implantable Miniature Telescope$136
- EYSUVIS$122
- INVELTYS$122
- TRYPTYR$120
- TearCare$117
- CEQUA$114
- TEPEZZA$110
- MIEBO$101
- XIIDRA$101
How this compares
$8,170 in reported general payments places this provider in the 95th percentile of 383 optometrist providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 15 | $17,379 |
| ProlensaBromfenac Sodium | 17 | $6,666 |
| Difluprednate | 54 | $5,418 |
| Prednisolone Acetate | 110 | $3,063 |
| MoxifloxacinMoxifloxacin Hcl | 92 | $2,214 |
| Latanoprost | 52 | $407 |
| Diclofenac Sodium | 20 | $221 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 16 | $150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $308 | $17,37915 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $90 | $6,66617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 383 optometrist providers in Nebraska.
Other optometrist in Omaha
- Christopher WolfeOmaha$154K
- Mark ToelleOmaha$10K
- Jordan ArensOmaha$7K
- Holly TernusOmaha$6K
- Marsha KubicaOmaha$6K
- Delaney KentOmaha$5K
- Adam WalterOmaha$5K
- Kelly RobertsonOmaha$5K
- Kristen WaltonOmaha$5K
- Kristin ReedOmaha$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.